
FARXIGA Approved for Pediatric Type-2 Diabetes in the US
AstraZeneca’s FARXIGA® (dapagliflozin) has received approval from the US Food and Drug Administration (FDA) for improving glycemic control in pediatric patients with type-2 diabetes (T2D) aged 10 years and older. This approval follows positive results from the pediatric T2NOW Phase…













